KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

Ming Lu, Min Jung Kim, Emily C Collins, Sergey Shcherbinin, Amy K Ellinwood, Yuma Yokoi, Dawn A Brooks, Oskar Hansson, David S Knopman, John R Sims, Mark A Mintun

JAMA Neurol 82(12) 1251-1256

PMID41082199
PMCIDPMC12687091
DOI10.1001/jamaneurol.2025.3869
发表日期2025-10-13
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

IMPORTANCE: Accumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. OBJECTIVE: To assess the correlation of posttreatment amyloid levels with clinical outcomes and biomarkers in AD. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc exploratory analysis from the randomized, placebo-controlled phase 3 trial, TRAILBLAZER-ALZ 2, conducted June 2020 through April 2023 at 277 medical research centers/hospitals in 8 countries. A total of 8240 participants aged 60 to 85 years with early symptomatic AD with amyloid and tau pathology based on positron emission tomography (PET) imaging were assessed for eligibility. Of these, 6504 participants were excluded predominantly due to inadequate amyloid or tau pathology. The current analysis included 1582 participants (766 in the donanemab group and 816 in the placebo group) with baseline and at least 1 posttreatment assessment. Data analysis took place from July 2024 to March 2025. INTERVENTIONS: Participants were randomized 1:1 to receive donanemab (700 mg for the first 3 doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks, with outcomes assessed through 76 weeks. MAIN OUTCOMES AND MEASURES: Participants were categorized into 1 of 10 groups (deciles) based on their lowest amyloid value observed posttreatment. Clinical progression was assessed via changes in integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores. Plasma biomarkers measured included phosphorylated tau 217 (p-tau217), p-tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Correlations between the median amyloid level in each decile were assessed with 76-week least-squares mean changes in each outcome and biomarker. RESULTS: Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo. The mean (SD) age was 72.9 (6.2) years, and 900 participants (56.9%) were female. Participants who received donanemab had lower posttreatment amyloid values than those in the placebo group. Across the trial population, lower posttreatment amyloid levels were correlated with slower clinical progression as measured by iADRS score (R2, 0.73 [95% CI, 0.37-0.97]) and CDR-SB score (R2, 0.87 [95% CI, 0.70-0.97]) and with decreases in p-tau217 (R2, 0.86 [95% CI, 0.73-0.97]), p-tau181 (R2, 0.88 [95% CI, 0.77-0.97]), and GFAP (R2, 0.87 [95% CI, 0.76-0.97]). There was no correlation between posttreatment amyloid value and NfL (R2, 0.03 [95% CI, 0.00-0.54]). CONCLUSIONS AND RELEVANCE: The findings in this secondary analysis of a randomized clinical trial demonstrating a correlation between posttreatment amyloid plaque level and clinical benefit support amyloid plaque removal as the mechanism of action for donanemab treatment and the level of amyloid plaque as a potential surrogate biomarker in amyloid-targeting therapies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04437511.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Participant Flow in a Trial of Donanemab for Early Symptomatic Alzheimer Disease (AD) and Population Used in the Post Hoc Analysis MMSE indicates Mini-Mental State Examination; MRI, magnetic resonance imaging. a Inclusion criteria for tau pathology: low/medium or high tau indicated by standardized uptake value ratio >1.10 or positive visual read assessed by 18 F-flortaucipir positron emission tomography (PET) imaging. b Inclusion criteria for amyloid pathology: ≥37 Centiloids, assessed with 18 F-florbetapir or 18 F-florbetaben PET. c Inclusion criteria for Mini-Mental State Examination: score of 20 to 28. d Phosphorylated tau 181 screening criterion was not implemented for the entire trial duration. e Exclusion criteria for magnetic resonance imaging include presence of amyloid-related imaging abnormalities of edema or effusion, >4 cerebral microhemorrhages, >1 area of superficial siderosis, and any intracerebral hemorrhage >1 cm or severe white matter disease. f Summary of other screen failure criteria can be found in Sims et al. g Stratified by baseline tau categorization and enrolling sites. h One additional death occurred after treatment completion in the follow-up period. i Alzheimer disease progression to a degree prompting study discontinuation, per investigator judgment. j Treatment completion criteria: amyloid plaque level of 11 Centiloids on any single scan or 11 to <25 Centiloids on 2 consecutive scans. k Participants who met treatment completion criteria are included in discontinuation and completion numbers.
非 KM Figure
Figure 2Figure 2.. Correlation of Posttreatment Amyloid Value With 76-Week Changes in Clinical Progression Measures Correlation of amyloid burden (Centiloids) with 76-week change in integrated Alzheimer’s Disease Rating Scale (iADRS) score (A) and Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) score (B). Least-squares (LS) mean changes were analyzed with mixed models for repeated measures (MMRM). MMRM models included deciles, visit, and deciles-by-visit interaction terms as fixed factors and were adjusted for baseline value, baseline-by-visit interaction, baseline age, concomitant acetylcholinesterase inhibitor and/or memantine use at baseline, and randomization stratifying factors (pooled investigator and baseline tau category). Models used an unstructured covariance matrix to model within-participant correlation.
非 KM Figure
Figure 3Figure 3.. Correlation of Posttreatment Amyloid Value With 76-Week Changes in Blood Biomarkers Correlation of amyloid burden (Centiloids) with 76-week change in phosphorylated tau 217 (p-tau217) (A), p-tau181 (B), glial fibrillary acidic protein (GFAP) (C), and neurofilament light chain (NfL) (D). Least-squares (LS) mean changes were analyzed with mixed models for repeated measures (MMRM). MMRM models included deciles, visit, and deciles-by-visit interaction terms as fixed factors and were adjusted for baseline value, baseline-by-visit interaction, baseline age, and baseline tau category. Models used an unstructured covariance matrix to model within-participant correlation.
非 KM Figure